AxoGen (NASDAQ:AXGN) Price Target Raised to $26.00 at Canaccord Genuity Group

AxoGen (NASDAQ:AXGN) had its target price increased by Canaccord Genuity Group from $22.00 to $26.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have a buy rating on the medical equipment provider’s stock.

AxoGen Price Performance

Shares of NASDAQ AXGN opened at $19.46 on Wednesday. AxoGen has a fifty-two week low of $5.55 and a fifty-two week high of $21.00. The company has a market cap of $856.43 million, a PE ratio of -60.81 and a beta of 1.00. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. The business has a 50-day simple moving average of $17.57 and a two-hundred day simple moving average of $14.96.

Institutional Trading of AxoGen

Large investors have recently bought and sold shares of the stock. Squarepoint Ops LLC raised its holdings in shares of AxoGen by 86.7% in the fourth quarter. Squarepoint Ops LLC now owns 55,668 shares of the medical equipment provider’s stock worth $917,000 after buying an additional 25,853 shares during the last quarter. State of Wyoming acquired a new position in shares of AxoGen in the 4th quarter valued at $31,000. ProShare Advisors LLC purchased a new position in AxoGen in the 4th quarter worth $197,000. Nicholas Investment Partners LP raised its stake in AxoGen by 49.9% in the 4th quarter. Nicholas Investment Partners LP now owns 295,554 shares of the medical equipment provider’s stock worth $4,871,000 after acquiring an additional 98,419 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in AxoGen by 4.0% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,128 shares of the medical equipment provider’s stock worth $398,000 after acquiring an additional 926 shares during the period. Hedge funds and other institutional investors own 80.29% of the company’s stock.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.